September 02, 2026 10:57 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
CJP calls off Sept 5 Delhi march after Supreme Court quashes FIRs against protesters | ‘Dismantle entire terror ecosystem’: Modi’s strong message at SCO Summit in Shehbaz’s presence | Modi’s big appeal after 7.8% GDP growth: ‘Don’t travel abroad, avoid destination weddings’ | Modi-Pezeshkian talks: Iran seeks India’s 'extensive contacts' to end West Asia war | Indus Waters Treaty row: India rejects Hague court order, says ‘no jurisdiction’ over its sovereign decisions | India beats the odds with 7.8% GDP growth; PM Modi has a message for critics | PM Modi meets Iranian President Masoud Pezeshkian during SCO summit in Kyrgyzstan | ‘Islam superior to all religions’: Karnataka minister’s remark sparks BJP-Congress war; resignation demand grows | PM Modi meets Iran's President Masoud Pezeshkian during SCO summit in Kyrgyzstan | VHP breaks silence on Durga Puja ‘guidelines’: No blanket non-veg ban, clarifies stand on theme pandals amid backlash
Instas Pharma

Abu Dhabi Investment Authority to buy stake in Instas Pharma

| @indiablooms | Apr 27, 2022, at 05:48 pm

The Abu Dhabi Investment Authority (ADIA), a sovereign wealth fund owned by the Emirate of Abu Dhabi, is going to acquire about 3 percent in Intas Pharmaceuticals for $250-$270 million (Rs 2,000 crore) at a valuation of $8.5 billion (Rs 65,000 crore), media reports said.

It will acquire the 3 percent stake from current investor Temasek Holdings, which presently holds about 10 percent in the Indian drug company, ET reported.

The Chudgar family, currently, owns 84 percent of the company, while homegrown PE fund ChrysCapital owns 6 percent, said the report.

ADIA has wide exposure in India with assets under management worth $800 billion., it added.

Its has invested in major Indian companies like Flipkart, Reliance Retail, Mindspace REIT, HDFC Capital, Mphasis, Paytm, Nykaa and Mobikwik.

Since 2018, ADIA has invested more than $3 billion in India, the report noted.

Intas Pharma is the seventh-largest domestic formulations company, with nearly 30 percent of its turnover locally, about 40 percent from the UK and European markets, and remaining from the United States and other markets.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.